Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its ...

Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation due to ...

A pair of top Democratic lawmakers asked the U.S. securities regulator on Wednesday to preserve records related to President ...

In the closing of the recent trading day, Pfizer (PFE) stood at $24.70, denoting a +0.65% change from the preceding trading day.

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

One of the most promising aspects of AI and its integration into the pharmaceutical industry is the technology’s potential to ...

Pfizer delayed the announcement of its COVID-19 vaccine until after the 2020 election when it thought Donald Trump was ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

Major pharmaceutical companies reap most of their profits in the U.S. but shift their tax burdens to low-tax havens such as ...

Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...